HEMOSTEMIX EXPANDS CLINICAL OPERATIONS WITH NEW PATIENT-CARE DIRECTOR
CALGARY, Alberta — December 4, 2025 — Hemostemix Inc., a leader in autologous stem-cell therapeutics, has appointed Shaune Harding,...
Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
CALGARY, Alberta — December 4, 2025 — Hemostemix Inc., a leader in autologous stem-cell therapeutics, has appointed Shaune Harding,...
THOUSAND OAKS, Calif., Oct. 1, 2025 — Amgen announced that its landmark VESALIUS-CV Phase 3 trial met primary endpoints...
DALLAS, Texas, September 12, 2025 — Ronovo Surgical has announced the launch of its latest line of advanced surgical...
MALVERN, Pennsylvania, September 10, 2025 — Elutia has announced the sale of its BioEnvelope business to Boston Scientific Corporation...
NEW YORK, September 8, 2025 — Biotia has introduced an innovative “test to treat” pathway for patients suffering from...
MINNEAPOLIS, August 29, 2025 — Phraxis announced the successful completion of the first-ever commercial case using its EndoForce Anastomotic...
